miR-885-5p suppresses hepatocellular carcinoma metastasis and inhibits Wnt/β-catenin signaling pathway. 2016

Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
Department of Immunology, School of Medicine, Nankai University, Tianjin, 300071, China.

MicroRNAs (miRNAs) inhibit or improve the malignant progression of hepatocellular carcinoma (HCC). We previously reported that compared to health controls, patients with liver cirrhosis present the highest levels of circulating miR-885-5p, followed by those with chronic hepatitis B and those with HCC. However, the molecular involvement of miR-885-5p in HCC metastasis is presently unclear. Here, we demonstrated that the expression of miR-885-5p negatively correlated with the invasive and metastatic capabilities of human HCC tissue samples and cell lines. We found that miR-885-5p expression levels correlated with the survival of patients with HCC. Overexpression of miR-885-5p decreased metastasis of HCC cells in vitro and in vivo. Inhibition of miR-885-5p improved proliferation of non-metastatic HCC cells. Furthermore, we disclosed that miR-885-5p targeted gene encoding β-catenin CTNNB1, leading to decreased activity of the Wnt/β-catenin signaling pathway. The present study indicates that miR-885-5p suppresses the metastasis of HCC and inhibits Wnt/β-catenin signaling pathway by its CTNNB1 target, which suggests that miR-885-5p to be a promising negative regulator of HCC progression and as a novel therapeutic agent to treat HCC.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
January 2021, Frontiers in cell and developmental biology,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
February 2024, Aging,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
February 2024, Journal of cellular and molecular medicine,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
January 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
November 2015, World journal of hepatology,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
December 2019, Cancer medicine,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
May 2024, Biochemical genetics,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
December 2021, Cell death & disease,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
May 2022, Cell death & disease,
Zhuhong Zhang, and Jing Yin, and Jian Yang, and Wenzhi Shen, and Chunyan Zhang, and Wenjun Mou, and Jinhua Luo, and Hua Yan, and Peiqing Sun, and Yunping Luo, and Yaping Tian, and Rong Xiang
January 2020, OncoTargets and therapy,
Copied contents to your clipboard!